Cost effectiveness of continuous positive airway pressure for sleep apnoea
Reducing the burden on the health system
Deloitte Access Economics has prepared a report for the Sleep Health Foundation that estimates the cost effectiveness of continuous positive airway pressure for obstructive sleep apnoea.
Obstructive sleep apnoea (OSA) is a common and costly sleep disorder in Australia, and in 2011, Deloitte Access Economics estimated the costs of OSA, including financial impacts and loss of wellbeing, at $21.2 billion.
Continuous positive airway pressure (CPAP) is a common, safe and effective form of treatment for people with OSA. In this latest report for the Sleep Health Foundation, the cost effectiveness of CPAP compared to no care has been considered from the perspective of the health system, and broader Australian society.
Given the substantial burden of OSA in Australia, cost effective interventions to treat OSA are essential to improve wellbeing and reduce the burden on the health system and society more broadly.
Published: November 2018